Loading…

Plasmalemmal K sub(ATP) channels shape triggered calcium transients in metabolically impaired rat atrial myocytes

The relative role of plasmalemmal and mitochondrial ATP-sensitive K super(+) (K sub(ATP)) channels in calcium homeostasis of the atrium is little understood. Electrically triggered (1 Hz) cytoplasmic calcium transients were measured by 340-to-380-nm wavelength fura 2 emission ratios in cultured rat...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Heart and circulatory physiology 2002-12, Vol.283 (6), p.H2296-H2305
Main Authors: Baumann, P, Poitry, S, Roatti, A, Baertschi, A J
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The relative role of plasmalemmal and mitochondrial ATP-sensitive K super(+) (K sub(ATP)) channels in calcium homeostasis of the atrium is little understood. Electrically triggered (1 Hz) cytoplasmic calcium transients were measured by 340-to-380-nm wavelength fura 2 emission ratios in cultured rat atrial myocytes. CCCP, a mitochondrial protonophore (100-400 nmol/l), dose dependently reduced the transient amplitude by up to 85%, caused a slow rise in baseline calcium, and reduced the recovery time constant of the transient from 143 to 91 ms (P < 0.05). However, neither 5-hydroxydecanoate, a mitochondrial K sub(ATP) channel blocker, nor diazoxide (500 mu mol/l) affected the amplitude, baseline, or time constant in CCCP-treated cells. HMR-1098 (30 mu mol/l), a plasmalemmal K sub(ATP) channel blocker, and glibenclamide (1 mu mol/l) increased the amplitude in CCCP-treated myocytes by 69-82%, sharply elevated the calcium baseline, and prolonged the recovery time constant to 181-193 ms (P < 0.01). Thus opening of plasmalemmal but not mitochondrial K sub(ATP) channels reduces the calcium overload in metabolically compromised but otherwise intact atrial myocytes. Mitochondrial K sub(ATP) channels probably operate through a different mechanism to afford ischemic protection.
ISSN:0363-6135
DOI:10.1152/ajpheart.00393.2002